WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

Firm News

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million. 

Stuart Falber led the WilmerHale team representing Tetraphase in this transaction, with a team that included Chris Barnstable-Brown, Emily Gainor and Tim Kulis

Visit www.tetraphase.com for more information. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.